Evidence map›Paper›PMID 22130607›Full record

ArticleEuropean journal of medicinal chemistry2012

First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.

Puranik Purushottamachar, Jyoti B Patel, Lalji K Gediya, Omoshile O Clement, Vincent C O Njar

Abstract read
In one paragraph

Article in European journal of medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Retinol Depletion in COVID-19.Clinical nutrition open science · 2022
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Establishment of a screening protocol for identification of aminopeptidase N inhibitors.Journal of the Taiwan Institute of Chemical Engineers · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Puranik PurushottamacharDepartment of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, 130 South 9th Street, Philadelphia, PA 19107, USA.
Jyoti B Patel
Lalji K Gediya
Omoshile O Clement
Vincent C O Njar

Funding

Development of VN/14-1 and Related Analogs for Breast Cancer TherapyR01CA129379 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI NJAR, VINCENT COLLINS OFUKA · 2010 to 2014
$2.5M
Retinoids, RAMBAs, and Histone Deacetylase InhibitorsR21CA117991 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI NJAR, VINCENT COLLINS OFUKA · 2005 to 2006
$347k
NCI NIH HHS 1R01CA129379-01 A2NCI NIH HHS 5R01CA129379-02NCI NIH HHS R01 CA129379NCI NIH HHS R21 CA117991NCI NIH HHS R21 CA117991-01
6 · The paper itself

Abstract

The first three-dimensional (3D) pharmacophore model was developed for potent retinoidal retinoic acid metabolism blocking agents (RAMBAs) with IC(50) values ranging from 0.0009 to 5.84nM. The seven common chemical features in these RAMBAs as deduced by the Catalyst/HipHop program include five hydrophobic groups (hydrophobes), and two hydrogen bond acceptors. Using the pharmacophore model as a 3D search query against NCI and Maybridge conformational Catalyst formatted databases; we retrieved several compounds with different structures (scaffolds) as hits. Twenty-one retrieved hits were tested for RAMBA activity at 100nM concentration. The most potent of these compounds, NCI10308597 and HTS01914 showed inhibitory potencies less (54.7% and 53.2%, respectively, at 100nM) than those of our best previously reported RAMBAs VN/12-1 and VN/14-1 (90% and 86%, respectively, at 100nM). Docking studies using a CYP26A1 homology model revealed that our most potent RAMBAs showed similar binding to the one observed for a series of RAMBAs reported previously by others. Our data shows the potential of our pharmacophore model in identifying structurally diverse and potent RAMBAs. Further refinement of the model and searches of other robust databases is currently in progress with a view to identifying and optimizing new leads.

Indexed as

Models, MolecularAntineoplastic AgentsCatalytic DomainCytochrome P-450 Enzyme SystemHumansReproducibility of ResultsRetinoic Acid 4-HydroxylaseTretinoinAntineoplastic AgentsCytochrome P-450 Enzyme SystemRetinoic Acid 4-HydroxylaseTretinoin

Identifiers

PMID22130607
PMCPMC3259215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.